Argus Research Upgrades Moderna to Buy, Announces $180 Price Target

Benzinga Newsdesk www.benzinga.com Positive 65.1%

Neg 0% Neu 0% Pos 65.1%

Argus Research analyst John Eade upgrades Moderna (NASDAQ:MRNA) from Hold to Buy and announces $180 price target.

Comments

No comments yet. Be the first!